retatrutide clinical trial safety data Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 retatrutide clinical trials safety data

The trial is expected to be completed in October 2024 (Nicholls et al., 2024)

Whats Included Online consultation, medication, shipping, and ongoing support from a healthcare provider for various concerns, such as dosing and side effects

10.1196/annals.1320.007

American Journal of Physiology - Endocrinology And Metabolism

Clinical nutrition research demonstrates that people eating these foods report lower hunger scores and consume fewer total calories without feeling deprived

Its primary function as a fat metabolism facilitator makes it a widely used compound in weight management , endurance performance , cardiovascular support , and metabolic health programs